drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An afucosylated human IgG1 monoclonal antibody that binds the BAFF receptor (BAFF-R/TNFRSF13C) on B cells, blocking BAFF/BLyS survival signaling and enhancing ADCC to deplete B cells; administered subcutaneously (e.g., 300 mg monthly).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
ianalumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated human IgG1 monoclonal antibody targeting BAFF receptor (BAFF‑R/TNFRSF13C) on B cells; blocks BAFF/BLyS survival signaling and enhances FcγR-mediated ADCC, leading to depletion of BAFF‑R–expressing B cells and reduced autoantibody production.
drug_name
Ianalumab (VAY736)
nct_id_drug_ref
NCT06293365